Development and validation of a dissolution test for delayed release capsule formulation of duloxetine hydrochloride

Current Pharmaceutical Analysis

Volumn 8, Issue 3, 2012, Pages 236-246

  Kumar, Navneet ^a,b   Sangeetha, Dhanaraj ^b   Reddy, Pingili Sunil ^a   Reddy, Annarapu Malleswara ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

^b VIT UNIVERSITY   (India)

Author keywords

Capsules; Development; Discriminating; Dissolution; Duloxetine; HPLC UV; LC MS MS; RRF; Validation

Indexed keywords

1 NAPHTHOL DERIVATIVE; ACETONITRILE; DULOXETINE; PHOSPHATE BUFFERED SALINE;

ACCURACY; ARTICLE; DRUG CAPSULE; DRUG DEGRADATION; DRUG FORMULATION; DRUG IMPURITY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; PH; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; ULTRAVIOLET RADIATION; VALIDATION STUDY;

EID: 84863899048     PISSN: 15734129     EISSN: 1875676X     Source Type: Journal    
DOI: 10.2174/157341212801619360     Document Type: Article

References (17)

1. http://www.ehs.lilly.com/msds/msds_duloxetine_hydrochlo ride_capsules.pdf
2. Westanmo, A. D.; Gayken, J.; Haight, R. Duloxetine: a balanced and selective norepinephrine and serotonin-reuptake inhibitor. Am. J. Health. Syst. Pharm., 2005, 62, 2481-2490.
3. Johnson, J.T.; Oldham, S.W.; Lantz, R.J.; DeLong, A.F. High performance liquid chromatographic method for the determination of duloxetine and desmethyl duloxetine in human plasma. J. Liq. Chromatogr. Relat. Technol., 1996, 19, 1631-1641.
4. Satonin, D.K.; McClloch, J.D.; Kuo, F.; Knadler, M.P. Development and validation of a liquid chromatography-tandem mass spectrometric method for the determination of the major metabolites of duloxetine in human plasma. J. Chromagr. B, 2007, 852, 582-589.
5. Selvan, S.P.; Gowda, V.K.; Mandal, U.; Solomon, S.W.D.; Pal, T.K. Determination of duloxetine in human plasma by liquid chromatography with atmospheric pressure ionization-tandem mass spectrometry and its application to pharmacokinetic study. J. Chromagr. B, 2007, 858, 269-257.
6. Dhaneshwar, S.S.; Deshpande, P.; Patil, M.; Vadnerkar, G.; Dhaneshwar, S.R. Development and validation of a HPTLC method for the estimation of duloxetine hydrochloride in bulk drug and in tablet dosage. Indian J. Pharm. Sci., 2008, 70, 233-236.
7. Kamila, M.M.; Mondal, N.; Ghosh, L.K. A validated UV spectrophotometric method for determination of duloxetine hydrochloride. Pharmazie, 2007, 62, 414-415.
8. Gomes, P.; Wingert, N.R.; Paim, C.S.; Schapoval, E.E.S.; Steppe, M. Stress degradation studies and kinetic determinations of du-loxetine enteric-coated pellets by HPLC. J. AOAC Int., 2010, 93, 1829-1835.
9. Patel, S.K.; Patel, N.J.; Prajapati, A.M.; Patel, D.B.; Patel, S.A. Stability-indicating RP-HPLC method development and validation for duloxetine hydrochloride in tablets. J. AOAC Int., 2010, 93, 123-129.
10. Raman, N.V.; Harikrishna, K.A.; Prasad, A.V.; Reddy, K.R.; Ramakrishna, K. Determination of duloxetine hydrochloride in the presence of process and degradation impurities by a validated stability-indicating RP-LC method. J. Pharm. Biomed. Anal., 2010, 51, 994-997.
11. th ed., The United States Pharmacopoeial Convention: 12601 Rockville, USA, 2011; pp. 278-284.
12. th ed., The United States Pharmacopoeial Convention: 12601 Rockville, USA, 2011; pp. 778-782.
13. th ed., The United States Pharmacopoeial Convention: 12601 Rockville, USA, 2011; pp. 624-630.
14. ICH Q2 (R1), Validation of Analytical Procedures: Text and Methodology, International Conference on Harmonization, 2005.
15. th ed., The United States Pharmacopoeial Convention: 12601 Rockville, USA, 2011; pp. 612-617.
16. FDA, Guidance for industry: Dissolution testing of immediate release solid oral dosage forms, Food and drug administration, Rockville, USA, 1997.
17. Moore, J.W.; Flanner, H.H. Mathematical comparison of dissolution profiles. Pharm. Technol., 1996, 20(6), 64-74.